These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35786135)

  • 1. Levalbuterol
    Chen L; Chen X; Zhi C; Li X; Hu Y
    J Med Econ; 2022; 25(1):966-973. PubMed ID: 35786135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
    Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
    Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
    Brunetti L; Poiani G; Dhanaliwala F; Poppiti K; Kang H; Suh DC
    Am J Health Syst Pharm; 2015 Jun; 72(12):1026-35. PubMed ID: 26025994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
    Truitt T; Witko J; Halpern M
    Chest; 2003 Jan; 123(1):128-35. PubMed ID: 12527613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of nebulized levalbuterol in stable COPD.
    Datta D; Vitale A; Lahiri B; ZuWallack R
    Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the Length of Stay and Economic Impact of Albuterol and Levalbuterol in Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study.
    Liu X; Zhang H; Yang Z; Ran Y; Qiu Y; Wang L; Zeng L; Li X; Zhi C; Lu J
    Cureus; 2024 Apr; 16(4):e59039. PubMed ID: 38803713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.
    Dalonzo GE
    J Am Osteopath Assoc; 2004 Jul; 104(7):288-93. PubMed ID: 15293593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Economic Impact of Levalbuterol's Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis.
    Tang T; Lin C; Zhi C; Li X; Wu Y
    Cureus; 2024 May; 16(5):e60640. PubMed ID: 38903381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
    Berger WE
    Ann Allergy Asthma Immunol; 2003 Jun; 90(6):583-91; quiz 591-2, 659. PubMed ID: 12839314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levalbuterol is not more cost-effective than albuterol for COPD.
    Hendeles L; Hartzema A
    Chest; 2003 Sep; 124(3):1176; author reply 1176-8. PubMed ID: 12970057
    [No Abstract]   [Full Text] [Related]  

  • 11. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
    Gawchik SM; Saccar CL; Noonan M; Reasner DS; DeGraw SS
    J Allergy Clin Immunol; 1999 Apr; 103(4):615-21. PubMed ID: 10200010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levalbuterol versus albuterol.
    Ameredes BT; Calhoun WJ
    Curr Allergy Asthma Rep; 2009 Sep; 9(5):401-9. PubMed ID: 19671384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED.
    Schreck DM; Babin S
    Am J Emerg Med; 2005 Nov; 23(7):842-7. PubMed ID: 16291438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population.
    Yuan J; Lu ZK; Zhang Y; Wu J; Love BL; Schulz RM
    Pediatr Pulmonol; 2017 Apr; 52(4):516-523. PubMed ID: 27701831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness of levalbuterol versus racemic albuterol.
    Quinn C
    Am J Manag Care; 2004 Jul; 10(5 Suppl):S153-7. PubMed ID: 15354680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator.
    Colice GL; Carnathan B; Sung J; Paramore LC
    J Asthma; 2005 Feb; 42(1):29-34. PubMed ID: 15801325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
    Carl JC; Myers TR; Kirchner HL; Kercsmar CM
    J Pediatr; 2003 Dec; 143(6):731-6. PubMed ID: 14657817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Inhaled Levalbuterol Compared to Albuterol in Horses with Recurrent Airway Obstruction.
    Arroyo MG; Couëtil LL; Nogradi N; Kamarudin MM; Ivester KM
    J Vet Intern Med; 2016 Jul; 30(4):1333-7. PubMed ID: 27282625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuterol and levalbuterol use and spending in Medicare beneficiaries with chronic obstructive pulmonary disease.
    Puig A; McElligott S; Bergquist H; Doshi JA
    Am J Geriatr Pharmacother; 2010 Dec; 8(6):571-82. PubMed ID: 21356506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.